OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
Top Cited Papers
- 17 March 2010
- journal article
- research article
- Published by SAGE Publications in Cephalalgia
- Vol. 30 (7), 793-803
- https://doi.org/10.1177/0333102410364676
Abstract
Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Methods: The Phase III REsearch Evaluating Migraine Prophylaxis Therapy 1 (PREEMPT 1) is a phase 3 study, with a 24-week, double-blind, parallel-group, placebo-controlled phase followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections every 12 weeks of onabotulinumtoxinA (155 U–195 U; n = 341) or placebo (n = 338) (two cycles). The primary endpoint was mean change from baseline in headache episode frequency at week 24. Results: No significant between-group difference for onabotulinumtoxinA versus placebo was observed for the primary endpoint, headache episodes (−5.2 vs. −5.3; p = 0.344). Large within-group decreases from baseline were observed for all efficacy variables. Significant between-group differences for onabotulinumtoxinA were observed for the secondary endpoints, headache days (p = .006) and migraine days (p = 0.002). OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few subjects discontinued due to adverse events. Conclusions: There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.Keywords
This publication has 39 references indexed in Scilit:
- Chronic migraine in the populationNeurology, 2008
- New Appendix Criteria Open for a Broader Concept of Chronic MigraineCephalalgia, 2006
- Chronic Daily HeadacheThe New England Journal of Medicine, 2006
- Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Primary chronic daily headache and its subtypes in adolescents and adultsNeurology, 2004
- Medication-overuse headache: a worldwide problemThe Lancet Neurology, 2004
- Chronic daily headacheNeurology, 2003
- Prevalence and description of chronic daily headache in the general population in FrancePain, 2003
- Epidemiology of Chronic Daily Headache in the General PopulationHeadache: The Journal of Head and Face Pain, 1999
- Prevalence of Frequent Headache in a Population SampleHeadache: The Journal of Head and Face Pain, 1998